AstraZeneca PLC · LSE:AZN

AstraZeneca — Merrill Lynch Conference New York 2004

28 slides from AstraZeneca's conference presentation, 2004

  1. Slide 1: David Brennan, President and CEO AstraZeneca US

    David Brennan President and CEO AstraZeneca US

  2. Slide 2: Headline results FY 03

    Headline results FY 03 2003 2002 Actual CER $m $m growth growth Sales 18,849 17,841 +6% - Operating profit 4,111 4,356 -6% -11% EPS (pre-excep) $1.78 $1.84 -3% -9% EPS $1.78 $1.64 +9% +3% Dividends $0.795 $0.70 Share repurchase $1,154m $1,190m

  3. Slide 3: 2003 sales by Therapy Area

    2003 sales by Therapy Area CER % adj CER growth % growth GI -16 +61 excl Losec®/Prilosec® CV +3 +19 excl Zestril® Oncology +8 +26 excl Nolvadex® Neuroscience +12 +12 Respiratory +15 +15 Total 0% +25%

  4. Slide 4: Strong sales performance offsets generic erosion

    Strong sales performance offsets generic erosion $m reported 2000 1000 Others 0 Neuro- science Onc -1000 Resp CV -2000 Prilosec® Zestril® -3000 Nolvadex® GI -4000

  5. Slide 5: 2003 other highlights

    2003 other highlights Launch of Crestor® First approval for Exanta® and regulatory submissions for key chronic indications Seroquel® approved for mania in bipolar disorder 14 compounds progressed to next phase of development 15 of high-quality candidate drugs entered into development

  6. Slide 6: AstraZeneca strategy

    AstraZeneca strategy 1999 2004 2008+ Deliver Top-tier financial performance Full potential of growth portfolio Drive Productivity for competitive Sustainable Platform for advantage growth for growth Expand long term Next wave of development projects In-house discovery External collaboration Broaden

  7. Slide 7: AstraZeneca: outperforming in many important growth markets

    AstraZeneca: outperforming in many important growth markets Asia Latin America C&EE 60 58% 40% 40 35% 24% 20 19% 14% 13% 12% 0 d. n ea a o nd l na zi di io ic Fe ra or hi la ex In eg -20 n C B Po K ia M R s us R IMS market growth AstraZeneca internal sales growth Source: IMS Health, IMS MIDAS; MAT S

  8. Slide 8: 2004 priorities

    2004 priorities Continue to build Crestor® into megabrand Drive Oncology portfolio Progress to US market leadership for Nexium® and Seroquel® First launches for Exanta® and register chronic claims Advance development projects Continuous improvement in productivity 2004 EPS range in range of $2. 00 t

  9. Slide 9: Growth product performance

    Growth product performance 9000 +45% 8000 7000 Crestor Faslodex 6000 Iressa Symbicort 5000 $m Nexium Arimidex 4000 Zomig Atacand 3000 Casodex Seroquel 2000 1000 0 FY 00 FY 01 FY 02 FY 03

  10. Slide 10: Crestor

    Crestor® First launch in Feb 03 in the Netherlands Crestor® profile • Lowers LDL-C by up to 63% across the dose range • Gets more patients to goal • HDL-C raising is maintained across dose range • Well tolerated, safety profile comparable to other marketed statins Approved in 44 markets and launched

  11. Slide 11: Crestor: early launch markets

    Crestor®: early launch markets 9.0 Netherlands 7.7 8.0 8.2 7.9 6.4 7.0 6.1 6.9 5.6 5.3 5.7 Canada 6.0 %TRx share 4.8 5.0 4.2 3.6 3.5 4.0 2.6 3.0 2.1 2.3 UK 1.9 2.9 2.6 2.0 1.4 1.0 1.9 2.4 1.0 0.5 1.7 1.0 1.4 0.2 0.6 0.0 0 Mth 1 Mth 2 Mth 3 Mth 4 Mth 5 Mth 6 Mth 7 Mth 8 Mth 9 Mth 10 Mth 11 Share of C

  12. Slide 12: Crestor: US launch tracking

    Crestor®: US launch tracking IMS New prescription data

  13. Slide 13: Crestor: US launch NRx

    Crestor®: US launch NRx Number of NRx NRx share Source: IMS Health, IMS NPA Plus - Retail, Mail Order, and Long Term Care. Share of C10A1 Statins. Jan. 2004

  14. Slide 14: Crestor: US launch tracking

    Crestor®: US launch tracking IMS New prescription data Dynamic market? Verispan VectorOne™ “New to brand” share • New and switch patients only

  15. Slide 15: Crestor: US launch dynamic share

    Crestor®: US launch dynamic share 50% Lipitor® 40% Share of Dynamic Patient Opportunities 30% 20% Zocor® Crestor® 13.7% 10% Lovastatin® Pravacho® All Others 0% k1 k3 k5 k7 k9 1 3 5 7 k1 k1 k1 k1 W W W W W W W W W Source: Verispan Instant VectorOne; Market = USC 32110

  16. Slide 16: Crestor: US launch tracking

    Crestor®: US launch tracking IMS New prescription data Dynamic market? Verispan VectorOne™ “New to brand” share • New and switch patients only Sampling impact? Other Market Research • Initiations including samples

  17. Slide 17: US Crestor NRx, dynamic share

    US Crestor® NRx 4.6% Dynamic share 13.7% Initiations including samples 20%* *Source: Impact Rx

  18. Slide 18: Oncology products

    Oncology products FY 03 sales up 8% to $2.7 billion (+26% ex. Nolvadex®) Casodex® up 22% to $854 million • Early prostate cancer Faslodex® sales $77 million • EU launches from 2Q 2004 Iressa® FY 03 sales $228 million • Japan $101 million • US $102 million - >42,000 retail Rx’s dispensed* Arimidex® u

  19. Slide 19: Arimidex: strong growth continues

    Arimidex®: strong growth continues 50,000 45,000 Arimidex® 40,000 35,000 30,000 25,000 20,000 letrozole 15,000 10,000 exemestane 5,000 0 2 3 1 3 1 2 2 2 2 2 3 3 3 -0 -0 -0 -0 -0 -0 -0 -0 -0 -0 -0 -0 -0 n n ct ct ct b b g ec ec r r g Ap Ju Ap Ju Fe Fe Au Au O O O D D Source: IMS Health, IMS MIDAS Mon

  20. Slide 20: ... with significant opportunity for continued growth

    … with significant opportunity for continued growth ATAC data 100% 90% 80% 88% tamoxifen 70% 77.1% 60% 50% 40% 30% 20% 14.8% Arimidex® 10% 6% letrozole 0% Jun-02 Jul-02 Jan-03 Jun-03 Jul-03 Nov-01 Jan-02 Nov-02 Sep-03 Dec-01 Feb-02 Mar-02 Ma y-02 Aug-02 Sep-02 Oct-02 Dec-02 Feb-03 Mar-03 Ma y-03 Aug

  21. Slide 21: Seroquel

    Seroquel® Full year sales $1,487 million; up 27% CER The only leading (top 3) atypical antipsychotic to grow market share* *Source: IMS Health, IMS MIDAS 2003

  22. Slide 22: Seroquel: US NRx in anti-psychotic market

    Seroquel®: US NRx in anti-psychotic market Market share 35% 30% Risperdal® 25% Zyprexa® Seroquel® 20% 15% 10% Abilify® 5% Geodon® 0% May-00 May-02 Mar-03 Mar-00 Jul-00 Mar-01 May-01 Jul-01 Mar-02 May-03 Jan-00 Nov-00 Jan-01 Nov-01 Jan-02 Jul-02 Sep-02 Nov-02 Jan-03 Jul-03 Nov-03 Sep-00 Sep-01 Sep-03

  23. Slide 23: Seroquel

    Seroquel® Full year sales $1,487 million; up 27% CER The only leading (top 3) atypical antipsychotic to grow market share* Bipolar mania approved in US and EU *Source: IMS Health, IMS MIDAS 2003

  24. Slide 24: Nexium market share of PPIs global markets

    Nexium® market share of PPIs global markets 70.0 59.6 60.0 Market Share % (USD) PPIs 50.0 42.0 40.0 36.4 30.0 26.2 23.0 23.1 22.6 18.8 19.2 20.0 13.2 11.1 12.8 9.6 10.0 7.8 2.3 0.0 ds ar k y li a y da n ium d n d e an in de a an A rla tr a l an nc ly na rw UK nm a US rm lg e th e l Sp Ita Fr a Fi n

  25. Slide 25: Total Prescription Market Share (PPI)

    Nexium® US TRx PPI market share 60% Total Prescription Market Share (PPI) 50% 40% 30% 20% 10% 0% 00 M 0 00 01 M 1 01 02 M 2 2 02 M 3 3 03 0 Se 0 00 1 Se 1 01 Se 2 02 03 Se 3 03 -0 -0 -0 -0 -0 -0 -0 l- 0 -0 l- 0 l- 0 l- 0 n- v- n- v- n- v- v- p- p- p- n- p- ar ar ay ay ar ar ay ay Ju Ju Ju Ju Ja Ja N

  26. Slide 26: Nexium US TRx GE market share

    Nexium® US TRx GE market share 40% 35% 30% 25% TRx Share 20% 15% 10% 5% 0% 1 2 3 1 1 2 3 2 2 3 3 -0 -0 -0 -0 -0 -0 -0 -0 -0 -0 -0 n n n ar ep ep ep ec ec ec ar Ju Ju Ju M M D D D S S S Prilosec® Nexium® Aciphex® Prevacid/pac® Protonix® generic omeprazole Source: IMS Health, IMS NPA Plus - Retail, Ma

  27. Slide 27: Nexium: strong performance in a changing US market

    Nexium®: strong performance in a changing US market 30 Nexium® 20 Prilosec® OTC launch 10 PPI TRx % ex omep growth 0 1st Qtr 2nd Qtr 3rd Qtr 4th Qtr -10 ome- -20 prazole -30 -40 Source: IMS Health, IMS NPA Plus - Retail, Mail Order, and Long Term Care. Dec 2003 Data. A2B2 Proton Pump Inhibitors. Tot

  28. Slide 28: David Brennan, President and CEO AstraZeneca US

    David Brennan President and CEO AstraZeneca US

AstraZeneca — Merrill Lynch Conference New York 2004 on 6ix